Log in

Relevant bibliographies by topics / Progression / Journal articles

Journal articles on the topic 'Progression'

To see the other types of publications on this topic, follow the link: Progression.

Author: Grafiati

Published: 4 June 2021

Last updated: 22 June 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Progression.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Arena, Julieta E., Stephen D. Weigand, Jennifer L. Whitwell, Anhar Hassan, Scott D. Eggers, Günter U. Höglinger, Irene Litvan, and Keith A. Josephs. "Progressive supranuclear palsy: progression and survival." Journal of Neurology 263, no. 2 (December 24, 2015): 380–89. http://dx.doi.org/10.1007/s00415-015-7990-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Wilson, Mark. "Measuring progressions: Assessment structures underlying a learning progression." Journal of Research in Science Teaching 46, no. 6 (August 2009): 716–30. http://dx.doi.org/10.1002/tea.20318.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hartmann, J. T., F. Heidel, J. Stoehlmacher, M. Duex, J. R. Izbicki, A. Elsaid, E. Wardelmann, T. Fischer, E. Jaeger, and S. Al-Batran. "Pattern of progression and its impact on outcome in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: A retrospective multicenter long-term follow-up study." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 9541. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.9541.

Full text

Abstract:

9541 Background: To investigate the clinical impact of the different types of disease progression (focal v extensive) in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) after initial response to imatinib. Methods: Pts who received imatinib for metastatic GIST at three Cancer Centers and who have been followed up for at least 2.5 years were eligible for the study. Disease progression was classified as focal or extensive as defined by protocol. Responses were evaluated according to WHO criteria. Progression-free survival (PFS) and overall survival (OS) were calculated according to the Kaplan-Meier-method. In three pts with focal progressions, serial biopsies were obtained for mutation analysis. Results: Thirty-eight patients (21 men; mean age 58.4 years; range, 37–73 years) were included in the analysis. After a median follow-up of 31.8 mos, 25 of 38 (65.8%) patients had progressed. Nine of 25 progressions were classified as focal and 16 as extensive. Salvage therapies included dose escalation of imatinib with or without surgical resection. Median and 6- and 12-mos PFS were 11.3 mos, 89%, and 40% in pts with focal progression, and 2.5 mos, 39%, and 32%, in patients with extensive progression, respectively. The median OS was 22.8 mos in pts with extensive progression, and was not reached in pts with focal progression. Two subsequent focal progressions in one pt were associated with 2 different secondary KIT-mutations, whereas non-progressive disease harbored the original KIT-mutation alone. Conclusions: Imatinib resistance seems to be partial in a subset of progressing GIST pts. These pts may benefit from local treatment and imatinib continuation and further investigation of imatinib combinations with other compounds appears warranted. Extensive progression is associated with a dismal survival. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

4

Plotkin, Daniel, Max Coleman, Derrick Van Every, Jaime Maldonado, Douglas Oberlin, Michael Israetel, Jared Feather, Andrew Alto, Andrew D. Vigotsky, and Brad J. Schoenfeld. "Progressive overload without progressing load? The effects of load or repetition progression on muscular adaptations." PeerJ 10 (September 30, 2022): e14142. http://dx.doi.org/10.7717/peerj.14142.

Full text

Abstract:

Background Progressive overload is a principle of resistance training exercise program design that typically relies on increasing load to increase neuromuscular demand to facilitate further adaptations. However, little attention has been given to another way of increasing demand—increasing the number of repetitions. Objective This study aimed to compare the effects of two resistance training programs: (1) increasing load while keeping repetition range constant vs (2) increasing repetitions while keeping load constant. We aimed to compare the effects of these programs on lower body muscle hypertrophy, muscle strength, and muscle endurance in resistance-trained individuals over an 8-week study period. Methods Forty-three participants with at least 1 year of consistent lower body resistance training experience were randomly assigned to one of two experimental, parallel groups: A group that aimed to increase load while keeping repetitions constant (LOAD: n = 22; 13 men, nine women) or a group that aimed to increase repetitions while keeping load constant (REPS: n = 21; 14 men, seven women). Subjects performed four sets of four lower body exercises (back squat, leg extension, straight-leg calf raise, and seated calf raise) twice per week. We assessed one repetition maximum (1RM) in the Smith machine squat, muscular endurance in the leg extension, countermovement jump height, and muscle thickness along the quadriceps and calf muscles. Between-group effects were estimated using analyses of covariance, adjusted for pre-intervention scores and sex. Results Rectus femoris growth modestly favored REPS (adjusted effect estimate (CI90%), sum of sites: 2.8 mm [−0.5, 5.8]). Alternatively, dynamic strength increases slightly favored LOAD (2.0 kg [−2.4, 7.8]), with differences of questionable practical significance. No other notable between-group differences were found across outcomes (muscle thicknesses, <1 mm; endurance, <1%; countermovement jump, 0.1 cm; body fat, <1%; leg segmental lean mass, 0.1 kg), with narrow CIs for most outcomes. Conclusion Both progressions of repetitions and load appear to be viable strategies for enhancing muscular adaptations over an 8-week training cycle, which provides trainers and trainees with another promising approach to programming resistance training.

APA, Harvard, Vancouver, ISO, and other styles

5

Bhavana S, Junagade, and Sabnis Anjali S. "Schizencephaly: A Neuronal Progression Disorder." Indian Journal of Anatomy 7, no. 2 (2018): 215–17. http://dx.doi.org/10.21088/ija.2320.0022.7218.19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Malpetti, Maura, Luca Passamonti, Peter Simon Jones, Duncan Street, Timothy Rittman, Timothy D. Fryer, Young T. Hong, et al. "Neuroinflammation predicts disease progression in progressive supranuclear palsy." Journal of Neurology, Neurosurgery & Psychiatry 92, no. 7 (March 17, 2021): 769–75. http://dx.doi.org/10.1136/jnnp-2020-325549.

Full text

Abstract:

IntroductionIn addition to tau pathology and neuronal loss, neuroinflammation occurs in progressive supranuclear palsy (PSP). However, the prognostic value of the in vivo imaging markers for these processes in PSP remains unclear. We test the primary hypothesis that baseline in vivo imaging assessment of neuroinflammation in subcortical regions predicts clinical progression in patients with PSP.MethodsSeventeen patients with PSP–Richardson’s syndrome underwent a baseline multimodal imaging assessment, including [11C]PK11195 positron emission tomography (PET) to index microglial activation, [18F]AV-1451 PET for tau pathology and structural MRI. Disease severity was measured at baseline and serially up to 4 years with the Progressive Supranuclear Palsy Rating Scale (PSPRS) (average interval of 5 months). Regional grey-matter volumes and PET ligand binding potentials were summarised by three principal component analyses (PCAs). A linear mixed-effects model was applied to the longitudinal PSPRS scores. Single-modality imaging predictors were regressed against the individuals’ estimated rate of progression to identify the prognostic value of baseline imaging markers.ResultsPCA components reflecting neuroinflammation and tau burden in the brainstem and cerebellum correlated with the subsequent annual rate of change in the PSPRS. PCA-derived PET markers of neuroinflammation and tau pathology correlated with regional brain volume in the same regions. However, MRI volumes alone did not predict the rate of clinical progression.ConclusionsMolecular imaging with PET for microglial activation and tau pathology can predict clinical progression in PSP. These data encourage the evaluation of immunomodulatory approaches to disease-modifying therapies in PSP and the potential for PET to stratify patients in early phase clinical trials.

APA, Harvard, Vancouver, ISO, and other styles

7

Bogucki, Andrzej, Justyna Pigońska, Iwona Szadkowska, and Agata Gajos. "Unilateral progressive muscular atrophy with fast symptoms progression." Neurologia i Neurochirurgia Polska 50, no. 1 (January 2016): 52–54. http://dx.doi.org/10.1016/j.pjnns.2015.10.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Gil‐Perotin, Sara, Carmen Alcalá, Francisco Carlos Pérez‐Miralles, and Bonaventura Casanova. "Silent Progression or Bout Onset Progressive Multiple Sclerosis?" Annals of Neurology 86, no. 3 (July 12, 2019): 472. http://dx.doi.org/10.1002/ana.25537.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Krug, Hollis E., Maren L. Mahowald, Paul B. Halverson, John D. Sallis, and Herman S. Cheung. "Phosphocitrate prevents disease progression in murine progressive ankylosis." Arthritis & Rheumatism 36, no. 11 (November 1993): 1603–11. http://dx.doi.org/10.1002/art.1780361116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Whitwell, Jennifer L., Jia Xu, Jay Mandrekar, Jeffrey L. Gunter, Clifford R. Jack, and Keith A. Josephs. "Imaging measures predict progression in progressive supranuclear palsy." Movement Disorders 27, no. 14 (March 13, 2012): 1801–4. http://dx.doi.org/10.1002/mds.24970.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Dickerson, Bradford C. "Quantitating Severity and Progression in Primary Progressive Aphasia." Journal of Molecular Neuroscience 45, no. 3 (May 15, 2011): 618–28. http://dx.doi.org/10.1007/s12031-011-9534-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Pugh, Siân A., Megan Bowers, Alexandre Ball, Stephen Falk, Meg Finch-Jones, Juan W. Valle, Derek A. O'Reilly, et al. "Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study." British Journal of Cancer 115, no. 4 (July 19, 2016): 420–24. http://dx.doi.org/10.1038/bjc.2016.208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Bovenzi, Matthew D., Jerome Sherman, and Sherry J. Bass. "Schnelle Progression zur poliferativen diabetischen Retinopathie." Optometry & Contact Lenses 2, no. 1 (December 29, 2021): 28–36. http://dx.doi.org/10.54352/dozv.pxzz4986.

Full text

Abstract:

Purpose. This case report illustrates rapid progression of diabetic retinopathy in a patient with poor compliance to diabetic management. It additionally demonstrates the utility of panoramic/ultra-wide field retinal imaging in assessing diabetic retinopathy progression. Material and Methods. A 42-year-old female patient was examined seven times over a 25 month period at a private ophthalmology/optometry practice with dilated fundus examinations. Fundus images were obtained using a pano- ramic/ultra-widefield laser retinal imager. Fluorescein angio- graphy (FA) was performed to assess for diabetic macular edema (DME), retinal ischemia and neovascularization, and laser photocoagulation was conducted as indicated by the clinical picture. Ophthalmic ultrasonography was performed to confirm tractional retinal detachments (TRD) at the final visit. Results. Initially, visual acuity was adequate (20/30; 6/9; LogMAR 0.18 in each eye) and the patient was diagnosed with moderate non-proliferative diabetic retinopathy. Diffuse leakage resulting in DME, confirmed with FA at the second visit, was treated with focal laser photocoagulation. However, after being lost to follow-up for over a year, her vision had deteriorated severely to finger counting at 1ft (30.5 cm) in the right eye, and 20/400; 6/120; LogMAR 1.30 in the left: the result of high-risk proliferative diabetic retinopathy in each eye. The patient underwent three treatments of pan-retinal photocoagulation (PRP), but she nevertheless developed tractional retinal detachments (TRD) in both eyes. Conclusion. The combination of poorly controlled diabetes and poor compliance with follow-up care in diabetic retino- pathy can lead to rapid progression of retinopathy and blind- ness. Early detection of diabetic retinopathy with panoramic/ ultra-wide field retinal imaging allows for appropriate staging and management of the disease, and ultimately, better visual outcomes. Keywords Diabetic retinopathy, proliferative diabetic retinopathy, panoramic retinal imaging, ultra-wide field retinal imaging, pan-retinal photocoagulation, tractional retinal detachment

APA, Harvard, Vancouver, ISO, and other styles

14

Phadke, Aryan. "Approximation of Sum of Harmonic Progression." International Journal of Science and Research (IJSR) 13, no. 1 (January 5, 2024): 1101–7. http://dx.doi.org/10.21275/sr24115160243.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Jeyapalan, Suriya A., Steven A. Toms, Andreas Felix Hottinger, Lawrence Kleinberg, Erqi Pollom, Scott G. Soltys, and Martin Glas. "Analysis of the EF-14 phase III trial reveals that tumor treating fields alter progression patterns in glioblastoma." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 2055. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.2055.

Full text

Abstract:

2055 Background: The EF-14 [NCT00916409] trial showed that addition of alternating electric fields (Tumor Treating Fields, TTFields) to Temozolomide (TMZ) resulted in improved survival in newly diagnosed Glioblastoma (GBM) patients with supratentorial tumors treated compared to TMZ alone. TTFields delivery is planned to optimize dose at the tumor bed, leading to the hypothesis that TTFields treated patients are more likely to exhibit distal progressions, including progression to the infratentorial brain where TTFields dose is minimal when targeting the supratentorium. Here we present analysis of the EF-14 trial testing this hypothesis. Methods: Patients on treatment for more than two months who had an MRI that exhibited progression were included in the study (treatment: N=280/466, control: N=122/229). Regions of enhancing tumor, necrosis and resection were contoured on T1 contrast MRIs acquired at baseline and at the date of first progression. New lesions at progression were classified as distal if they appeared outside of a Proximal Boundary Zone (PBZ) of 20 mm surrounding the lesions identified in the baseline MRI. The rate of occurrence of distal progressions in the TTFields-treated arm was compared to the rate observed in the control arm. Patients with (distal) infratentorial progression were identified. Results: Distal progressions were more common in the treatment arm (49/280 (18%) vs. 10/122 (8%) P<0.02; chi-squared). Infratentorial progression were observed in 4% (10 patients) of the treatment arm vs. 0 patients in the control (P<0.002 t-test). Distal lesions at progression were more distant from the original lesion in the TTFields treated arm (58.57 + 28.12 mm vs 46.61 + 20.48 mm, P<0.02; Wilcoxon rank sum test. The relative tumor growth rates in TTFields treated patients were significantly slower than those observed in the control arm (0.036+ 0.126 ml/day vs. 0.036+ 0.183 ml/day P<0.03; t-test). Conclusions: This analysis indicates that adding TTFields to TMZ could impact GBM growth patterns. The results suggest that TTFields increases local control of tumor growth, emphasizing the need for adaptive treatment after progression to control progressing disease. Clinical trial information: NCT00916409.

APA, Harvard, Vancouver, ISO, and other styles

16

Kim, Chul, Nitin Roper, Chuong D. Hoang, Eva Szabo, Maureen Connolly, Emerson Padiernos, Aparna Hemant Kesarwala, et al. "Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e20545-e20545. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e20545.

Full text

Abstract:

e20545 Background: EGFR tyrosine kinase inhibitors (EGFR-TKIs) improve progression-free survival (PFS) in patients with EGFR-mutant NSCLC, but disease progression limits efficacy. Retrospective studies show a survival benefit to LAT in patients with oligoprogressive disease (progression at a limited number of anatomic sites). Methods: This is a prospective study of LAT in patients with oligoprogressive EGFR-mutant NSCLC. Patients with no prior EGFR-TKI therapy (cohort 1) or progression after 1st/2ndgeneration EGFR-TKIs with acquired T790M mutation (cohort 2) receive osimertinib. Upon progression, eligible patients with < = 5 progressing sites undergo LAT and resume osimertinib until disease progression. Patients previously treated with osimertinib qualifying for LAT upon disease progression are also eligible for treatment (cohort 3). Primary endpoint: evaluation of safety and efficacy of reinitiation of osimertinib after LAT (assessed by PFS). Additional goals are assessment of mechanisms of resistance to osimertinib by multi-omics analyses of tumor, blood, and saliva. Results: Between 04/2016 and 01/2017, 15 patients were enrolled (cohort 1: 9, cohort 2: 3, cohort 3: 3). Median age was 57 (range 36-71). Treatment was well tolerated. The most common adverse events (AEs) were rash, diarrhea, thrombocytopenia, and alanine transaminase elevation. Grade 3/4 AEs were observed in 4 (27%) patients. Among evaluable patients, objective response rates prior to LAT in cohorts 1 and 2 were 71% (5/7) and 100% (2/2), respectively, with 6.8 months median PFS (95% CI: 3.4 months-undefined) in cohort 1 and no progressions in cohort 2. To date, 5 patients (33%; cohort 1: 2; cohort 3: 3) had LAT. Two patients with 3 progressing sites underwent a combination of surgery and radiation. Three patients with 1 progressing site underwent surgery alone. Post-LAT PFS and results of molecular analyses will be presented. Conclusions: Patients with EGFR-mutant NSCLC and oligoprogression after EGFR-TKI therapy can be safely treated with LAT. In selected patients, this approach could potentially maximize duration of EGFR-TKI treatment and prevent premature switching to other systemic therapies. Clinical trial information: NCT02759835.

APA, Harvard, Vancouver, ISO, and other styles

17

Lysén, M. "Progression." Pleiades: Literature in Context 36, no. 1 (2016): 41. http://dx.doi.org/10.1353/plc.2016.0049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Hinchman, Kathleen A., and Kelly Chandler‐Olcott. "Progression." Journal of Adolescent & Adult Literacy 63, no. 4 (December 27, 2019): 369–70. http://dx.doi.org/10.1002/jaal.1036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Nath, A., A. Venkataramana, D. S. Reich, I. Cortese, and E. O. Major. "Progression of progressive multifocal leukoencephalopathy despite treatment with -interferon." Neurology 66, no. 1 (January 9, 2006): 149–50. http://dx.doi.org/10.1212/01.wnl.0000191322.93310.a1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Skromne, E., V. M. Rivera, D. Ontaneda, L. Ordonez, A. Nath, A. Venkataramana, D. S. Riech, I. Cortese, and E. O. Major. "Progression of progressive multifocal leukoencephalopathy despite treatment with -interferon." Neurology 66, no. 11 (June 12, 2006): 1787–88. http://dx.doi.org/10.1212/01.wnl.0000230563.29202.6a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

De Moraes, Carlos Gustavo, Sara R. Ghobraiel, Robert Ritch, and Jeffrey M. Liebmann. "Comparison of PROGRESSOR and Glaucoma Progression Analysis 2 to Detect Visual Field Progression in Treated Glaucoma Patients." Asia-Pacific Journal of Ophthalmology 1, no. 3 (2012): 135–39. http://dx.doi.org/10.1097/apo.0b013e3182531e34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Leung, Christopher. "Comparison of PROGRESSOR Versus Glaucoma Progression Analysis 2 to Detect Visual Field Progression in Treated Glaucoma Patients." Asia-Pacific Journal of Ophthalmology 1, no. 4 (2012): 251. http://dx.doi.org/10.1097/apo.0b013e31826000eb.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Sanna, Carlo. "Covering an arithmetic progression with geometric progressions and vice versa." International Journal of Number Theory 10, no. 06 (August 14, 2014): 1577–82. http://dx.doi.org/10.1142/s1793042114500456.

Full text

Abstract:

We show that there exists a positive constant C such that the following holds: Given an infinite arithmetic progression [Formula: see text] of real numbers and a sufficiently large integer n (depending on [Formula: see text]), there is a need of at least Cn geometric progressions to cover the first n terms of [Formula: see text]. A similar result is presented, with the role of arithmetic and geometric progressions reversed.

APA, Harvard, Vancouver, ISO, and other styles

24

Pitot, H. C., and Y. P. Dragan. "Stage of Tumor Progression, Progressor Agents, and Human Risk." Experimental Biology and Medicine 202, no. 1 (January 1, 1993): 37–43. http://dx.doi.org/10.3181/00379727-202-43511f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

M.G.S., Dilanthi. "Empirical Progression of Lean Manufacturing: Literature Review." International Journal of Engineering Research 3, no. 11 (November 1, 2014): 657–61. http://dx.doi.org/10.17950/ijer/v3s11/1107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

ThinkaKamara, Emmanuel. "Deviation for Numbers in An Arithmetic Progression." International Journal of Science and Research (IJSR) 13, no. 3 (March 5, 2024): 1111–12. http://dx.doi.org/10.21275/es24301151237.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

O'Connor, Paul. "Interferon-β1b reduced the progression of secondary progressive multiple sclerosis." ACP Journal Club 130, no. 3 (May 1, 1999): 69. http://dx.doi.org/10.7326/acpjc-1999-130-3-069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Caffarra, Paolo, Simona Gardini, Stefano Cappa, Francesca Dieci, Letizia Concari, Federica Barocco, Caterina Ghetti, Livia Ruffini, and Guido Dalla Rosa Prati. "Degenerative Jargon Aphasia: Unusual Progression of Logopenic/Phonological Progressive Aphasia?" Behavioural Neurology 26, no. 1-2 (2013): 89–93. http://dx.doi.org/10.1155/2013/965782.

Full text

Abstract:

Primary progressive aphasia (PPA) corresponds to the gradual degeneration of language which can occur as nonfluent/agrammatic PPA, semantic variant PPA or logopenic variant PPA. We describe the clinical evolution of a patient with PPA presenting jargon aphasia as a late feature. At the onset of the disease (ten years ago) the patient showed anomia and executive deficits, followed later on by phonemic paraphasias and neologisms, deficits in verbal short-term memory, naming, verbal and semantic fluency. At recent follow-up the patient developed an unintelligible jargon with both semantic and neologistic errors, as well as with severe deficit of comprehension which precluded any further neuropsychological assessment. Compared to healthy controls, FDG-PET showed a hypometabolism in the left angular and middle temporal gyri, precuneus, caudate, posterior cingulate, middle frontal gyrus, and bilaterally in the superior temporal and inferior frontal gyri. The clinical and neuroimaging profile seems to support the hypothesis that the patient developed a late feature of logopenic variant PPA characterized by jargonaphasia and associated with superior temporal and parietal dysfunction.

APA, Harvard, Vancouver, ISO, and other styles

29

Haley, E. C., N. F. Kassell, and J. C. Torner. "Failure of heparin to prevent progression in progressing ischemic infarction." Stroke 19, no. 1 (January 1988): 10–14. http://dx.doi.org/10.1161/01.str.19.1.10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Robinson, Richard. "What New Understanding of Progressive MS Reveals About Disease Progression." Neurology Today 19, no. 12 (June 2019): 25–26. http://dx.doi.org/10.1097/01.nt.0000569664.72043.62.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Marrodan, M., C. Bensi, A. Pappolla, J. I. Rojas, M. I. Gaitán, M. C. Ysrraelit, L. Negrotto, et al. "Disease activity impacts disability progression in primary progressive multiple sclerosis." Multiple Sclerosis and Related Disorders 39 (April 2020): 101892. http://dx.doi.org/10.1016/j.msard.2019.101892.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Kosa, Peter, Tianxia Wu, Jonathan Phillips, Mika Leinonen, Ruturaj Masvekar, Mika Komori, Alison Wichman, Mary Sandford, and Bibiana Bielekova. "Idebenone does not inhibit disability progression in primary progressive MS." Multiple Sclerosis and Related Disorders 45 (October 2020): 102434. http://dx.doi.org/10.1016/j.msard.2020.102434.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Gao, Hui-Ming, and Jau-Shyong Hong. "Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression." Trends in Immunology 29, no. 8 (August 2008): 357–65. http://dx.doi.org/10.1016/j.it.2008.05.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Jabbari, Edwin, John Woodside, and Huw Morris. "PO082 Can csf nfl predict progression in progressive supranuclear palsy?" Journal of Neurology, Neurosurgery & Psychiatry 88, Suppl 1 (December 2017): A33.1—A33. http://dx.doi.org/10.1136/jnnp-2017-abn.113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Cree, Bruce A. C., and Stephen L. Hauser. "Reply to “Silent Progression or Bout Onset Progressive Multiple Sclerosis?”." Annals of Neurology 86, no. 3 (July 12, 2019): 472–73. http://dx.doi.org/10.1002/ana.25536.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Rojas, Julio C., Anna Karydas, Jee Bang, Richard M. Tsai, Kaj Blennow, Victor Liman, Joel H. Kramer, et al. "Plasma neurofilament light chain predicts progression in progressive supranuclear palsy." Annals of Clinical and Translational Neurology 3, no. 3 (February 2016): 216–25. http://dx.doi.org/10.1002/acn3.290.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Sudha, AndeJeevana, Chaturbhuj Rathore, Sunil Kumar, and Gowtham Yeeli. "Rapidly progressive dementia: Clue lies in the speed of progression." Journal of Integrated Health Sciences 9, no. 2 (2021): 125. http://dx.doi.org/10.4103/jihs.jihs_20_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Sim, Kai An, and Kok Bin Wong. "Magic Square and Arrangement of Consecutive Integers That Avoids k-Term Arithmetic Progressions." Mathematics 9, no. 18 (September 14, 2021): 2259. http://dx.doi.org/10.3390/math9182259.

Full text

Abstract:

In 1977, Davis et al., proposed a method to generate an arrangement of [n]={1,2,…,n} that avoids three-term monotone arithmetic progressions. Consequently, this arrangement avoids k-term monotone arithmetic progressions in [n] for k≥3. Hence, we are interested in finding an arrangement of [n] that avoids k-term monotone arithmetic progression, but allows k−1-term monotone arithmetic progression. In this paper, we propose a method to rearrange the rows of a magic square of order 2k−3 and show that this arrangement does not contain a k-term monotone arithmetic progression. Consequently, we show that there exists an arrangement of n consecutive integers such that it does not contain a k-term monotone arithmetic progression, but it contains a k−1-term monotone arithmetic progression.

APA, Harvard, Vancouver, ISO, and other styles

39

Gouveia, Anna Sophia Almeida, Laura Beatriz Wuensch Weschenfelder, Juliana Limberger Heinze, and Antônio Manoel de Borba Junior. "Mielopatia compressiva com progressão atípica / Compressive myelopathy with atypical progression." Brazilian Journal of Health Review 4, no. 3 (June 22, 2021): 13699–707. http://dx.doi.org/10.34119/bjhrv4n3-313.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Bancin, Martin, Andi Wete Polili, and Nurilam Harianja. "ANALYSE DE PROGRESSION THEMATIQUE LINÉAIRE DANS LE TEXTE DESCRIPTIF." HEXAGONE Jurnal Pendidikan, Linguistik, Budaya dan Sastra Perancis 5, no. 1 (June 28, 2016): 92. http://dx.doi.org/10.24114/hxg.v5i1.3915.

Full text

Abstract:

RÉSUMÉ Le but de cette recherche est pour trouver les progressions thématiques utilisées dans le journal Le Monde surtout la progression thématique linéaire. En les trouvant, cette recherche a pour but aussi de trouver les formes de progression linéaire. La méthode de la recherche est la méthode qualitative. La méthode qualitative est un procès de la recherche qui produit la donnée descriptive comme le mot à l’écrit ou à l’oral des personnes observées. Cette méthode de recherche va expliquer une condition de vérité et donner la priorité à la donnée que la théorie. Pour analyser les données, l’auteur analyse25 textes descriptifs qui sont trouvés dans le journal Le Monde. Le résultat de la recherche indique la progression thématique du thème linéaire presque dans tous les faits divers que l’auteur du journal écrit. Les progressions thématiques trouvées dans 24 de 25 faits divers que l’auteur analyse comme la source des données dans cette recherche. L’auteur du journal Le Monde préfère aussi utiliser la progression thématique du thème constant dans un fait divers. Il utilise souvent la progression dérivé quand ils doivent citer quelques points dans sa nouvelle. Après avoir analysé 25 textes descriptifs dans le journal Le Monde, on trouve quelques formes de la progression thématique du thème linéaire que l’auteur du journal utilisée. On trouve la variation des progressions thématique du thème linéaire selon la théorie que l’auteur utilise dans cette recherche. Les formes des la progression linéaire sont en forme de l’emploie des adjectifs, des démonstratifs et des possessifs. Il y aussi le développement thématique qui utilise des synonymies, de la répétition d’un mot, etc. Mots Clés : Progression Thématique, Progression Linéaire, Journal, Forme.

APA, Harvard, Vancouver, ISO, and other styles

41

J. Kramer, Holly, and Sankar D. Navaneethan. "CKD Progression." Nephrology Self-Assessment Program 18, no. 4 (September 2019): 202–9. http://dx.doi.org/10.1681/nsap.2019.18.4.4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Joudan, Shira. "Postdoc progression." Nature Chemistry 14, no. 10 (September 27, 2022): 1089–90. http://dx.doi.org/10.1038/s41557-022-01053-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Bridges, Glenys. "Optimising progression." Dental Nursing 18, no. 3 (March 2, 2022): 116–19. http://dx.doi.org/10.12968/denn.2022.18.3.116.

Full text

Abstract:

Glenys Bridges discusses proactive CPD choices for dental nurses with extended duties Aims To define CPD requirements for dental nurses performing extended duties. To identify the implications of GDC Principle 7.2 on dental nurse development. Objectives To be able to recognise a range of proactive development opportunities for dental nurses. To be able to make informed choices to select CPD programmes that progress confidence and competence. To be able to select CPD opportunities that reflect ongoing learning needs. To be able to use record-keeping, peer review and reflective practice to implement ongoing personal and professional development. GDC development outcome B and D

APA, Harvard, Vancouver, ISO, and other styles

44

Benner, Steven A. "Natural progression." Nature 409, no. 6819 (January 2001): 459. http://dx.doi.org/10.1038/35054149.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Martinez-Conde, Susana. "Age progression." Nature 527, no. 7578 (November 2015): 404. http://dx.doi.org/10.1038/527404a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Rosneck, James S., Donna Waechter, Donald A. Noe, and Richard Josephson. "EXERCISE PROGRESSION." Journal of Cardiopulmonary Rehabilitation and Prevention 27, no. 5 (September 2007): 337. http://dx.doi.org/10.1097/01.hcr.0000291359.16946.54.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Elder, David E. "Melanoma progression." Pathology 48, no. 2 (February 2016): 147–54. http://dx.doi.org/10.1016/j.pathol.2015.12.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Calabrese, Peter, Simon Tavaré, and Darryl Shibata. "Pretumor Progression." American Journal of Pathology 164, no. 4 (April 2004): 1337–46. http://dx.doi.org/10.1016/s0002-9440(10)63220-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Einecke, Dirk. "Progression gebremst." MMW - Fortschritte der Medizin 156, no. 21-22 (December 2014): 100. http://dx.doi.org/10.1007/s15006-014-3834-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Swami, Meera. "Monitoring progression." Nature Reviews Cancer 9, no. 4 (April 2009): 229. http://dx.doi.org/10.1038/nrc2630.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!